US 12,007,376 B2
Method for determining a concentration of a synthesis component in a radiopharmaceutical sample
Artem Y. Lebedev, Santa Monica, CA (US); and Arkadij M. Elizarov, Woodland Hills, CA (US)
Assigned to Trace-Ability, Inc., Van Nuys, CA (US)
Filed by Trace-Ability, Inc., Van Nuys, CA (US)
Filed on Dec. 15, 2020, as Appl. No. 17/122,496.
Application 17/122,496 is a division of application No. 14/866,684, filed on Sep. 25, 2015, granted, now 10,895,563.
Application 14/866,684 is a continuation in part of application No. 14/191,293, filed on Feb. 26, 2014, granted, now 10,309,947, issued on Jun. 4, 2019.
Claims priority of provisional application 62/171,183, filed on Jun. 4, 2015.
Claims priority of provisional application 62/056,529, filed on Sep. 27, 2014.
Prior Publication US 2021/0102929 A1, Apr. 8, 2021
Int. Cl. G01N 33/15 (2006.01); C12M 1/34 (2006.01); C12Q 1/02 (2006.01); G01N 21/78 (2006.01); G01N 21/82 (2006.01); A61B 6/03 (2006.01); G01N 21/25 (2006.01); G01N 21/51 (2006.01); G01N 21/75 (2006.01); G01N 33/00 (2006.01)
CPC G01N 33/15 (2013.01) [C12M 41/36 (2013.01); C12Q 1/02 (2013.01); G01N 21/78 (2013.01); G01N 21/82 (2013.01); A61B 6/037 (2013.01); G01N 21/253 (2013.01); G01N 21/51 (2013.01); G01N 2021/752 (2013.01); G01N 2033/0093 (2013.01)] 19 Claims
 
1. A method for determining a concentration of a synthesis component in a radiopharmaceutical sample, comprising:
providing a metal complex as a liquid solution;
contacting the radiopharmaceutical sample in the form of a liquid solution with the metal complex for a period of time sufficient to form a modified metal complex;
measuring an optical characteristic of the modified metal complex; and
determining a concentration of the synthesis component in the radiopharmaceutical sample based on the measured optical characteristic via mathematical calculations.
 
13. A method for determining a concentration of a synthesis component in a radiopharmaceutical sample, comprising:
providing an indicator as a liquid solution;
contacting the radiopharmaceutical sample in the form of a liquid solution sample with the indicator for a period of time sufficient for interaction of the synthesis component with the indicator;
measuring an optical characteristic of the indicator and synthesis component after their interaction; and
determining a concentration of the synthesis component in the radiopharmaceutical sample based on the measured optical characteristic.